Setmelanotide
GMP ISO 4 Inquiries
920014-72-8
Research and Industrial Grade
98%
GT peptide
Plastic bottles
Yes
2022-04-15
Pharmaceutical Peptide,Cosmetic peptide,Custom peptides,API polypeptide,Amino acids and derivatives,Peptide - Teriparatide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Setmelanotide is a synthetic peptide and selective melanocortin-4 receptor (MC4R) agonist. As a peptide-based pharmaceutical raw material, Setmelanotide is characterized by its defined molecular structure and receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.
CertificatesBasic Info-
Product Name:
Setmelanotide
Other Name:Setmelanotide;920014-72-8;UNII-N7T15V1FUY;BIM-22493;RM-493;Imcivree;N7T15V1FUY;(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide;Setmelanotide [USAN:INN];GTPL9272
CAS No.:920014-72-8
Molecular Formula:C49H68N18O9S2
InChIKeys:HDHDTKMUACZDAA-PHNIDTBTSA-N
Molecular Weight:1117.31
Exact Mass:1116.49
UNII:N7T15V1FUY
ATC Code:A08AA
Categories:
Characteristics-
PSA:
494.76
XLogP3:3.0807
Research-
Class:
MC4R (melanocortin-4 receptor) agonist (8-amino-acid cyclic peptide)
Status:FDA-approved (Imcivree 2020) — orphan drug for genetic obesity
Mechanism:A first-in-class, 8-amino-acid cyclic peptide (Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2) that acts as a selective MC4R agonist. MC4R is a key regulator of hunger, satiety, and energy expenditure in the hypothalamus. Setmelanotide restores melanocortin signaling in patients with genetic defects in the leptin-melanocortin pathway, producing significant weight loss without cardiovascular side effects.
EC50 (Human Mc4r Ki):2.1 nM
EC50 (Human Mc4r Ec50):0.27 nM
Source:DrugBank: DB11700; ChemicalBook: CAS 920014-72-8; target validation: Chen C, et al.
Clinical Development:FDA:Imcivree (approved 2020-11-25)
References-
DrugBank:PubChem:Literature:
FDA: Imcivree (NDA 213793); NEJM: Clément K, et al. (2020) — Setmelanotide for POMC deficiency
Disclaimer:Setmelanotide is FDA-approved as a prescription medicine (Imcivree) for rare genetic forms of obesity (POMC/LEPR deficiency, Bardet-Biedl syndrome, Alström syndrome). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Pharmaceutical Peptide,Cosmetic peptide,Custom peptides,API polypeptide,Amino acids and derivatives,Peptide - Teriparatide
-
Location:
5th Floor, Building 1, No. 600 Yinhai Street, Xiasha Street
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
7 days
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2014
-
-
Inquiry History4 Inquiries
Country Product Purchase Quantity Date Posted
Singapore
Setmelanotide
1 G Aug 8, 2026
United Kingdom
Setmelanotide
1 G Dec 17, 2024
United Kingdom
Setmelanotide
1 G Dec 17, 2024
United States
Setmelanotide
2 G May 20, 2024 Post an enquiry for this product
More from this Seller
-
-
-
Tripeptide-1 CAS NO.72957-37-0
Research grade
-
-
-
-
Fmoc-D-Trp-OH
Research and Industrial Grade / 98.00%
-
-
-
-
Angiotensin I-Converting Enzyme Substrate
Research and Industrial Grade / 98.00%
-
-
-
-
Z-D-Lys-OH
Research and Industrial Grade / 98.00%
-
-
-
-
Collagen Type II Fragment
Research and Industrial Grade / 98.00%
-